Waregem (Belgium) / Rotterdam (The Netherlands)[1], 30 September 2014 -Arseus announces today that Pharmacy Services Inc. has acceded as a “Guarantor” and two companies, Duo-Med NV and Dutch Biofarmaceutics B.V., have been removed as a “Guarantor” from the Guarantor List. This is in accordance with the Guarantee Declaration dated 12 June 2012 regarding the € 225,000,000 4.75% Bond with maturity date 2 July 2017:
The list of Guarantors, in accordance with Article 10.4 of the Guarantee Declaration, is available at www.arseus.com.
In accordance with Condition 10 (b) of the Bonds a new Compliance Certificate is published. This Compliance Certificate is available at www.arseus.com.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
For further information:
Marieke Palstra
Director Investor Relations
+ 31 88 33 11 213
Arseus profile
Arseus is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Arseus consists of two divisions: Fagron and HL Technology. Fagron supplies pharmaceutical raw materials, equipment & supplies, concepts and pharmaceutical compounding to pharmacies and hospital pharmacies in 30 countries. Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron’s own R&D organization consists of 200 pharmacists who are working continually on developing new formulations for specific patients and patient groups. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals.
The Belgian company Arseus NV is located in Waregem and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
[1] This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the press release: